May 12, 2020
Catabasis Phase 3 PolarisDMD trial for edasalonexent in Duchenne expected in Q4
Catabis expects top-line results in Q4 2020 from fully enrolled edasalonexent global phase 3 PolarisDMD trial in duchenne muscular dystrophy.